Investors / Germany / OCCIDENT
OCCIDENT
Venture capital · Munich, Germany · Europe
OCCIDENT is an owner-managed venture capital investor that invests its own money in deep-tech startups, focusing on spin-offs from scientific research. It supports portfolio companies financially and with operational experience, and states it has 15 active portfolio companies and 7 exits.
Invests inHealthcare & BiotechIndustrial & Manufacturing
In its own wordsdeep techlife sciencesbiotechspin-offsscienceimpact
Your fit with OCCIDENT
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsOCCIDENT lists 18 checked portfolio companies on its own site and is named in 1 funding round, 1 of them as lead. Its most frequent entry is Pre-seed, 100% of the companies with a known first round. Its largest themes are Healthcare & Biotech (71%), Industrial & Manufacturing (18%) and Enterprise Software (6%). 50% of its companies are based in Switzerland. It invests most often alongside CDP Venture Capital, EFI Lake Geneva Ventures and FONGIT.
Counts come from funding rounds that name OCCIDENT, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not OCCIDENT's whole history. Rounds on record name 1 company; its own site lists 18. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 100% |
| Seed | 0% |
| Series A | 0% |
| Series B | 0% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 0 | 0 |
| '26 | 1 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 46th | 18 companies |
| Recent activity | 59th | 1 rounds in 12 months |
| Early stage | 100th | 100% of entries at pre-seed or seed |
| Evidence | 65th | 6% of companies confirmed by a round |
| Sector focus | 92th | 71% in its largest sector |
| Reach | 58th | 3 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| CDP Venture Capital | 2 |
| EFI Lake Geneva Ventures | 2 |
| FONGIT | 2 |
| High-Tech Gründerfonds | 2 |
| Redalpine | 2 |
| Alpana Ventures | 1 |
| Ascenta Capital | 1 |
| Backbone Ventures | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers18100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 71% | 15% |
| Industrial & Manufacturing | 18% | 7% |
| Enterprise Software | 6% | 8% |
| Media & Entertainment | 6% | 4% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with CDP Venture Capital
Compare OCCIDENT head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with OCCIDENT| Date | Company | Stage |
|---|---|---|
| 21 Jul 2026 | Pre-Seed Led |
Round details for OCCIDENT
Amounts, full round histories and every co-investor in OCCIDENT's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
18 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Adivo is part of an integrated brand that transforms life sciences with other organizations. | Healthcare & Biotech | Portfolio page | ||
| Algiax Pharmaceuticals develops innovative treatments for chronic neuropathic pain | Healthcare & Biotech | Portfolio page | ||
| Altavo is a medical device startup that works to help voiceless people regain their own, natural-sounding voice using non-invasive silent speech technology | Healthcare & Biotech | Portfolio page | ||
| Avelo develops a breath sampling kit for diagnosing respiratory infectious diseases | Healthcare & Biotech | Portfolio page | ||
| Chipmetrics provides productized test chips and wafers and their analysis expertise for demanding 3D applications of thin films. | Industrial & Manufacturing | Portfolio page | ||
| The company develops and manufactures wireless sensors and measurement technology for various applications, including torque measurement and condition monitoring. | Industrial & Manufacturing | Portfolio page | ||
| Ebamed develops a system for real-time target tracking and motion management in radiotherapy treatments | Healthcare & Biotech | Portfolio page | ||
| Hemotune develops a magnetic nanoparticle platform for targeted magnetic separation in medicine and biomanufacturing. | Healthcare & Biotech | Portfolio page | ||
| Immitra Bio is developing an in-vivo gene editing platform to cure genetic diseases | Healthcare & Biotech | Jul 2026Pre-Seed | Page + round | |
| The company provides tools and services for musicians to distribute and promote their music online. | Enterprise SoftwareMedia & Entertainment | Portfolio page | ||
| InSphero develops and provides 3D in vitro models for non-animal drug testing | Healthcare & Biotech | Portfolio page | ||
| Lunaphore enables spatial biology in every lab with its technology and products | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| ReCatalyst develops a nanotech catalyst platform to reduce dependency on scarce raw materials | Industrial & Manufacturing | Portfolio page | ||
| Resistell develops rapid phenotypic antibiotic susceptibility testing solutions | Healthcare & Biotech | Portfolio page | ||
| Thermosome is a drug development company focused on targeted tumor therapy combined with immune stimulation for improved cancer therapy. | Healthcare & Biotech | Portfolio page | ||
| Tubulis generates uniquely matched antibody-drug conjugates for cancer treatment | Healthcare & Biotech | Portfolio page | ||
| Portfolio page |
About this data
site last read 5 Nov 2026- Site
- occident.group
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 21 Jul 2026
- Companies checked
- 18
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get OCCIDENT's profile as data
Pull OCCIDENT's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/occident.group
# also
GET /v1/firms/occident.group/portfolio
GET /v1/firms/occident.group/coinvestors
GET /v1/firms/occident.group/news